Modzelewska Aneta, Pettit Catherine, Achanta Geetha, Davidson Nancy E, Huang Peng, Khan Saeed R
Division of Chemical Therapeutics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.
Bioorg Med Chem. 2006 May 15;14(10):3491-5. doi: 10.1016/j.bmc.2006.01.003. Epub 2006 Jan 24.
A series of novel chalcones and bis-chalcones containing boronic acid moieties has been synthesized and evaluated for antitumor activity against the human breast cancer MDA-MB-231 (estrogen receptor-negative) and MCF7 (estrogen receptor-positive) cell lines and against two normal breast epithelial cell lines, MCF-10A and MCF-12A. These molecules inhibited the growth of the human breast cancer cell lines at low micromolar to nanomolar concentrations, with five of them (1-4, 9) showing preferential inhibition of the human breast cancer cell lines. Furthermore, bis-chalcone 8 exhibited a more potent inhibition of colon cancer cells expressing wild-type p53 than of an isogenic cell line that was p53-null.
一系列含有硼酸部分的新型查尔酮和双查尔酮已被合成,并针对人乳腺癌MDA - MB - 231(雌激素受体阴性)和MCF7(雌激素受体阳性)细胞系以及两种正常乳腺上皮细胞系MCF - 10A和MCF - 12A进行了抗肿瘤活性评估。这些分子在低微摩尔至纳摩尔浓度下抑制人乳腺癌细胞系的生长,其中五种(1 - 4、9)对人乳腺癌细胞系表现出优先抑制作用。此外,双查尔酮8对表达野生型p53的结肠癌细胞的抑制作用比对p53缺失的同基因细胞系更强。